Mo. Favorov et al., SEROLOGIC IDENTIFICATION OF HEPATITIS-E VIRUS-INFECTIONS IN EPIDEMIC AND ENDEMIC SETTINGS, Journal of medical virology, 36(4), 1992, pp. 246-250
Recombinant chimeric protein C2 containing the N-terminal region of tr
pE (37 kilodaltons [kDa]) and the C-terminal half (46.8 kDa) of the po
lypeptide encoded by ORF2 of the hepatitis E virus (HEV) genome was us
ed for the construction of a Western blot diagnostic test for IgG and
IgM antibodies to the virus (anti-HEV). (The C2 protein and the trpE p
rotein devoid of C2 activity and used as a control for non-specific re
actions were purified by recovery from sodium dodecyl sulfate-polyacry
lamide gel electrophoresis [SDS-PAGE] and used for preparation of stri
ps). Specificity of the test was proven with sera obtained from patien
ts with acute hepatitis non-A, non-B, non-C (NANBNC) from outbreaks in
different geographic regions of the world. IgG antibodies reactive to
the recombinant C2 protein were detected in 93% of patients with acut
e hepatitis NANBNC and remained detectable in 89-100% of these patient
s 1-24 months after onset of jaundice. IgM antibodies were detected in
73% of patients within 26 days after onset of jaundice, in 50% 1-4 mo
nths after onset, in 6% 6-7 months after onset, and in no patients by
8 months after onset. When this test was used to identify sporadic hep
atitis E cases in different regions of the world, such cases were foun
d almost exclusively in areas where outbreaks of the disease had occur
red and rarely in any other regions.